Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

29th Annual Miami Breast Cancer Conference Opens

March 14th 2012

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

Miami Breast Cancer Conference Founder Keeps Focus on Future

March 12th 2012

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. Schnabel Discusses the DCIS Recurrence Score

March 9th 2012

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Taking a Leap in Cancer Diagnostics: Clarient Enters New Era in Molecular Tumor Testing, Drug Discovery Research

March 9th 2012

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Harvey Discusses Preventing Breast Cancer

March 8th 2012

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

Assay Offers Molecular Analysis of Breast Cancer Risk Recurrence: Interview With Kenneth J. Bloom, MD

March 7th 2012

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Dr. Baselga Discusses the BOLERO Breast Cancer Trials

March 5th 2012

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Targeting HER2: Pertuzumab Puts the Spotlight on Dual Blockade Strategies

March 2nd 2012

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

2 Leading Breast Cancer Researchers Discuss Emerging Anti-HER2 Therapeutics

March 1st 2012

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Dr. Solin on Personalizing Treatment With the DCIS Score

February 28th 2012

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

A Family Tradition: The Personal Story Behind the Miami Breast Cancer Conference

February 28th 2012

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Dr. Burris on Using Recurrence Scores to Predict pCR

February 23rd 2012

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Perez Discusses Optimizing Adjuvant Therapy

February 22nd 2012

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Schnabel on Predicting Breast Cancer by Atypia Type

February 21st 2012

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harvey on Aromatase Inhibitor Treatment Duration

February 20th 2012

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

2 Landmark Trials Suggest Changes in Practice; Brachytherapy Controversy Attracts Attention

February 20th 2012

This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.

Premature Tamoxifen Withdrawal Is Common in Male Patients With Breast Cancer

February 20th 2012

New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Navigation Program Shows Limited Benefit in Underserved, Urban Women With Breast Cancer

February 15th 2012

The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.

Breast Cancer is Diagnosed Later in Men but Is Less Often Fatal

February 14th 2012

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.